Mediar Therapeutics has entered a global licensing agreement with Eli Lilly and Company to progress the human immunoglobulin G1 (IgG1) antibody, MTX-463, into a Phase II trial for the treatment of ...

Eli Lilly (NYSE:LLY) has entered into a licensing agreement with Mediar Therapeutics to advance Mediar's drug MTX-463 into Phase 2 testing for idiopathic pulmonary fibrosis. Mediar said it expects to ...

Financial writer cautious on Eli Lilly stock despite strong performance, citing high valuation and underperforming drugs.

N-Power Medicine, backed by Merck GHI, announced the acquisition of Syapse Holdings. Samsung Biologics and LigaChem extended their ADC services deal. Publicis Worldwide merged with Leo Burnett to form ...

Mediar Therapeutics is planning to launch a Phase 2 clinical trial in the first half of 2025 to test its IPF therapy MTX-463.

The partnership aims to advance the idiopathic pulmonary fibrosis therapy into a Phase II trial. Credit: Andrey_Popov/Shutterstock. Mediar Therapeutics has entered a ...

Eli Lilly’s idiopathic pulmonary fibrosis deal with Mediar is centered around MTX-463, an anti-WISP1 antibody that early studies have found to be safe and capable of engaging its target. Eli Lilly on ...

Disgusted by Democrats’ ongoing support for the genocide in Gaza, some Muslim and Arab American voters are embracing third-party candidates and community-based forms of political engagement ...